| References: |
AI-10-49 selectively binds to CBFβ-SMMHC and disrupts its binding to RUNX1. AI-10-49 restores RUNX1 transcriptional activity, displays favorable pharmacokinetics, and delays leukemia progression in mice. Treatment of primary inv(16) AML patient blasts with AI-10-49 triggers selective cell death. For the detailed information of AI-10-49, the solubility of AI-10-49 in water, the solubility of AI-10-49 in DMSO, the solubility of AI-10-49 in PBS buffer, the animal experiment (test) of AI-10-49, the cell expriment (test) of AI-10-49, the in vivo, in vitro and clinical trial test of AI-10-49, the EC50, IC50,and affinity,of AI-10-49, For the detailed information of AI-10-49, the solubility of AI-10-49 in water, the solubility of AI-10-49 in DMSO, the solubility of AI-10-49 in PBS buffer, the animal experiment (test) of AI-10-49, the cell expriment (test) of AI-10-49, the in vivo, in vitro and clinical trial test of AI-10-49, the EC50, IC50,and affinity,of AI-10-49, Please contact DC Chemicals. |
